132 related articles for article (PubMed ID: 6810900)
1. Effect of an aromatase inhibitor, 1,4,6-androstatriene-3,17-dione, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat and its mechanism of action in vivo.
Brodie AM; Brodie HJ; Garrett WM; Hendrickson JR; Marsh DA; Tsai-Morris CH
Biochem Pharmacol; 1982 Jun; 31(11):2017-23. PubMed ID: 6810900
[TBL] [Abstract][Full Text] [Related]
2. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
Brodie AM; Garrett WM; Hendrickson JR; Tsai-Morris CH
Cancer Res; 1982 Aug; 42(8 Suppl):3360s-3364s. PubMed ID: 6805949
[TBL] [Abstract][Full Text] [Related]
3. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
Wing LY; Garrett WM; Brodie AM
Cancer Res; 1985 Jun; 45(6):2425-8. PubMed ID: 3921242
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors--IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione.
Brodie AM; Marsh D; Brodie HJ
J Steroid Biochem; 1979 Apr; 10(4):423-9. PubMed ID: 109701
[No Abstract] [Full Text] [Related]
5. Antifertility effects of an aromatase inhibitor, 1,4,6-androstatriene-3, 17-dione.
Brodie AM; Wu JT; Marsh DA; Brodie HJ
Endocrinology; 1979 Jan; 104(1):118-21. PubMed ID: 446339
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
De Coster R; Van Ginckel RF; Callens MJ; Goeminne NK; Janssens BL
Cancer Res; 1992 Mar; 52(5):1240-4. PubMed ID: 1737385
[TBL] [Abstract][Full Text] [Related]
7. A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors.
Zaccheo T; Giudici D; Lombardi P; di Salle E
Cancer Chemother Pharmacol; 1989; 23(1):47-50. PubMed ID: 2491793
[TBL] [Abstract][Full Text] [Related]
8. The effect of the aromatase inhibitor, 4-(phenylthio)-4-androstene-3,17-dione, on dimethylbenz(A)anthracene-induced rat mammary tumors.
Abul-Hajj YJ
J Steroid Biochem; 1989; 34(1-6):439-42. PubMed ID: 2516585
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of aromatization stimulates luteinizing hormone and testosterone secretion in adult male rhesus monkeys.
Ellinwood WE; Hess DL; Roselli CE; Spies HG; Resko JA
J Clin Endocrinol Metab; 1984 Dec; 59(6):1088-96. PubMed ID: 6541658
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
Nishino Y; Schneider MR; Michna H; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat.
Yamamoto T; Urabe M; Tamura T; Kitawaki J; Honjo H; Okada H
Anticancer Res; 1991; 11(6):1999-2002. PubMed ID: 1776832
[TBL] [Abstract][Full Text] [Related]
12. Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
Brueggemeier RW; Li PK
Cancer Res; 1988 Dec; 48(23):6808-10. PubMed ID: 3141048
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ovarian aromatase by prolactin in vivo.
Tsai-Morris CH; Ghosh M; Hirshfield AN; Wise PM; Brodie AM
Biol Reprod; 1983 Sep; 29(2):342-6. PubMed ID: 6685537
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
15. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.
Brodie AM; Schwarzel WC; Shaikh AA; Brodie HJ
Endocrinology; 1977 Jun; 100(6):1684-95. PubMed ID: 404132
[TBL] [Abstract][Full Text] [Related]
16. Differential responses of sex steroid target tissues of rats treated with 4-hydroxyandrostenedione.
Wing LY; Hammond JO; Brodie AM
Endocrinology; 1988 Jun; 122(6):2418-27. PubMed ID: 3131115
[TBL] [Abstract][Full Text] [Related]
17. Administration of an aromatase inhibitor during the late follicular phase of gonadotropin-treated cycles in rhesus monkeys: effects on follicle development, oocyte maturation, and subsequent luteal function.
Zelinski-Wooten MB; Hess DL; Baughman WL; Molskness TA; Wolf DP; Stouffer RL
J Clin Endocrinol Metab; 1993 Apr; 76(4):988-95. PubMed ID: 8473415
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.
Schieweck K; Bhatnagar AS; Batzl C; Lang M
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):633-6. PubMed ID: 8476774
[TBL] [Abstract][Full Text] [Related]
19. Effect of an inhibitor of aromatization, 1,4,6 androstatriene-3,17-dione (ATD) on LH release and steroid binding in hypothalamus of adult female rats.
Slama A; Gogan F; Sarrieau A; Vial M; Rostene W; Kordon C
Exp Brain Res; 1986; 64(3):407-10. PubMed ID: 3803480
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours.
Zaccheo T; Giudici D; Ornati G; Panzeri A; di Salle E
Eur J Cancer; 1991; 27(9):1145-50. PubMed ID: 1835626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
